# Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors

> **NCT00462553** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 37 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage III Pancreatic Cancer
- Stage IV Pancreatic Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** sunitinib malate
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00462553
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2010-06
- **Final completion:** —
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2014-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00462553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00462553, "Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00462553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*